24/7 Market News Snapshot 07 October, 2025 – Verrica Pharmaceuticals Inc. Common Stock (NASDAQ:VRCA)

October 7, 2025

DENVER, Colo., 07 October, 2025 (www.247marketnews.com) – (NASDAQ:VRCA) are discussed in this article.
Verrica Pharmaceuticals Inc. (VRCA) is experiencing a notable bullish trend in the market, with shares opening at $4.66 and climbing to a high of $5.496, marking a significant increase of 17.19%. This surge is backed by a strong trading volume of 1.53 million shares, indicating an elevated interest among investors and reinforcing positive sentiment around the company. The upward trajectory reflects potential implications from recent developments regarding its innovative product pipeline, suggesting a promising outlook for continued momentum if the trading conditions remain favorable.

In line with this positive market performance, Verrica Pharmaceuticals is poised to make a significant impact at the upcoming Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, scheduled for November 5–9, 2025. The company will present its cutting-edge oncolytic peptide, VP-315, which is being explored as a first-in-class immunotherapy for the treatment of basal cell carcinoma (BCC). This approach aims to induce immunogenic cell death in tumors, thereby leveraging the body’s immune system to combat skin cancers without surgical intervention.

The conference will feature an oral presentation by Dr. Kenneth Y. Tsai of the Moffitt Cancer Center on November 5, 2025, wherein he will discuss promising findings from a phase 2 multicenter study assessing local immune activation after 12 weeks of VP-315 treatment. In addition, a poster session will provide a deeper analysis of the exploratory study, highlighting collaborative insights from leading experts.

Verrica Pharmaceuticals anticipates engaging with peers and stakeholders at SITC and is committed to advancing the treatment options available in dermatology, as the innovative VP-315 continues to pave the way for novel therapies targeting significant unmet medical needs in skin oncology.

Related news for (VRCA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.